ATC Group: C02KX01 Bosentan

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of C02KX01 in the ATC hierarchy

Level Code Title
1 C Cardiovascular system
2 C02 Antihypertensives
3 C02K Other antihypertensives
4 C02KX Antihypertensives for pulmonary arterial hypertension
5 C02KX01 Bosentan

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route Amount
ORAL - Oral 0.25 g

Active ingredients in C02KX01

Active Ingredient Description
Bosentan

Bosentan is a dual endothelin receptor antagonist (ERA) with affinity for both endothelin A and B (ETA and ETB) receptors. Bosentan decreases both pulmonary and systemic vascular resistance resulting in increased cardiac output without increasing heart rate.

Related product monographs

Title Information Source Document Type  
TRACLEER Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC

Medicines in this ATC group

United States (US)

Australia (AU)

Austria (AT)

Brazil (BR)

Canada (CA)

Croatia (HR)

Cyprus (CY)

Estonia (EE)

Finland (FI)

France (FR)

Germany (DE)

Hong Kong (HK)

Ireland (IE)

Israel (IL)

Italy (IT)

Japan (JP)

Lithuania (LT)

Mexico (MX)

Netherlands (NL)

New Zealand (NZ)

Poland (PL)

Romania (RO)

Singapore (SG)

Spain (ES)

Tunisia (TN)

United Kingdom (UK)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.